Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Abdo A Elfiky, Abdo A Elfiky

Abstract

Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).

Materials and methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.

Key findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.

Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.

Keywords: COVID-19; Docking; Nucleotide inhibitors; RdRp; Sofosbuvir; Structural bioinformatics; Wuhan coronavirus.

Conflict of interest statement

Declaration of competing interest The author declares that there is no competing interest in this work.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
(A) Multiple sequence alignment of all the HCoV strains (229E, NL63, HKU1, OC43, MERS, SARS, and COVID-19) RdRp sequences. Red highlights indicate identical residues while yellow highlighted residues are less conserved. Secondary structures are represented at the top of the MSA for SARS RdRp (PDB ID: 6NUR, chain A), while the surface accessibility is shown at the bottom (blue: highly accessible while white is buried). The black dashed rectangles mark active site aspartates while blue rectangles mark the residues lying in the 5 Å region surrounding the active aspartates. The alignment is made using the Clustal omega web server and represented by ESpript 3. (B) The newly emerged COVID-19 RdRp model built by Swiss Model in the green cartoon (right) and surface (left) representations. Two views of the polymerase at 180o rotation on the horizontal plane are shown (top and bottom). The active site aspartates are represented in red sticks for clarification (see the enlarged panel). (C) Ramachandran plot for the COVID-19 RdRp model. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 1
Fig. 1
(A) Multiple sequence alignment of all the HCoV strains (229E, NL63, HKU1, OC43, MERS, SARS, and COVID-19) RdRp sequences. Red highlights indicate identical residues while yellow highlighted residues are less conserved. Secondary structures are represented at the top of the MSA for SARS RdRp (PDB ID: 6NUR, chain A), while the surface accessibility is shown at the bottom (blue: highly accessible while white is buried). The black dashed rectangles mark active site aspartates while blue rectangles mark the residues lying in the 5 Å region surrounding the active aspartates. The alignment is made using the Clustal omega web server and represented by ESpript 3. (B) The newly emerged COVID-19 RdRp model built by Swiss Model in the green cartoon (right) and surface (left) representations. Two views of the polymerase at 180o rotation on the horizontal plane are shown (top and bottom). The active site aspartates are represented in red sticks for clarification (see the enlarged panel). (C) Ramachandran plot for the COVID-19 RdRp model. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Binding energies calculated by AutoDock Vina for GTP, UTP, IDX-184, Sofosbuvir, Ribavirin, Remdisivir, Cinnamaldehyde, and Thymoquinone against COVID-19 (blue) and SARS HCoV (orange) RdRps. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3
Fig. 3
(A) The interactions that established after docking the DAA drugs IDX-184, Sofosbuvir, and Ribavirin against COVID-19 RdRp are presented. DAAs are in orange while the protein active site pocket in cyan sticks. H-bonds in solid blue lines while hydrophobic interactions are in dashed lines. Salt bridges are in yellow spheres connected by dashed lines. Its one-letter code labels RdRp residues, and the docking scores are listed under each complex. (B) The overall 3D structure complexes arranged as (A). Protein is represented in ribbon, and ligands are in sticks while the interacting residues of the RdRp are represented in colored lines. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

References

    1. Bogoch I.I., Watts A., Thomas-Bachli A., Huber C., Kraemer M.U.G., Khan K. Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel. Journal of Travel Medicine. 2020
    1. Hui D.S., Azhar I.E., Madani T.A., Ntoumi F., Kock R., Dar O. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264–266.
    1. Organization WH . World Health Organization; 2020. Surveillance Case Definitions for Human Infection With Novel Coronavirus (nCoV): Interim Guidance v1, January 2020.
    1. Organization WH . World Health Organization; 2020. Infection Prevention and Control during Health Care When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance, January 2020.
    1. Organization WH . World Health Organization; 2020. Laboratory Testing of Human Suspected Cases of Novel Coronavirus (nCoV) Infection: Interim Guidance, 10 January 2020.
    1. Parr J. British Medical Journal Publishing Group; 2020. Pneumonia in China: Lack of Information Raises Concerns Among Hong Kong Health Workers.
    1. Elfiky A.A.I., N. S . 2020. Anti-SARS and Anti-HCV Drugs Repurposing Against the Papain-like Protease of the Newly Emerged Coronavirus (2019-nCoV) preprint.
    1. Ibrahim I.M.A., Elshahat D.H., Elfiky M.M., Abdo A. 2020. COVID-19 Spike-host Cell Receptor GRP78 Binding Site Prediction. preprint.
    1. Yang L. 2020. China Confirms Human-to-Human Transmission of Coronavirus.
    1. Chan J.F., Lau S.K., To K.K., Cheng V.C., Woo P.C., Yuen K.-Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 2015;28:465–522.
    1. Elfiky A.A., Mahdy S.M., Elshemey W.M. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J. Med. Virol. 2017;89:1040–1047.
    1. WHO . WHO; 2016. Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
    1. Báez-Santos Y.M., Mielech A.M., Deng X., Baker S., Mesecar A.D. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J. Virol. 2014;88:12511–12527.
    1. Hemida M.G., Alnaeem A. Some one health based control strategies for the Middle East respiratory syndrome coronavirus. One Health. 2019;8:100102.
    1. Organization WH . World Health Organization; 2019. Clinical Management of Severe Acute Respiratory Infection When Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection Is Suspected: Interim Guidance.
    1. Elfiky A.A. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol. 2016;88:2044–2051.
    1. Elfiky A.A. Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase. Futur. Virol. 2017;12:721–728.
    1. Elfiky A.A. Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study. Med. Chem. 2019;15:130–137.
    1. Elfiky A.A., Elshemey W.M. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med. Chem. Res. 2016;25:1005–1008.
    1. Elfiky A.A., Elshemey W.M. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. J. Med. Virol. 2018;90:13–18.
    1. Elfiky A.A., Elshemey W.M., Gawad W.A., Desoky O.S. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 2013;32:75–80.
    1. Elfiky A.A., Ismail A. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV. Life Sci. 2019;238:116958.
    1. Elfiky A.A., Ismail A.M. Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor. Futur. Virol. 2017;12:339–347.
    1. Ganesan A., Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin. Drug Discovery. 2017;12:407–425.
    1. Doublie S., Ellenberger T. The mechanism of action of T7 DNA polymerase. Curr. Opin. Struct. Biol. 1998;8:704–712.
    1. Elfiky A.A., Ismail A.M. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ. Res. 2018;29:409–418.
    1. Ezat A.A., Elfiky A.A., Elshemey W.M., Saleh N.A. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. VirusDisease. 2019;30(2):207–213.
    1. Yang P.L., Gao M., Lin K., Liu Q., Villareal V.A. Anti-HCV drugs in the pipeline. Curr Opin Virol. 2011;1:607–616.
    1. Markland W., McQuaid T., Jain J., Kwong A. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 2000;44:859–866.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020:1–3.
    1. McQuaid T., Savini C., Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol. 2015;3:27–35.
    1. Berman H., Henrick K., Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Mol Biol. 2003;10 980–.
    1. NCBI National Center of Biotechnology Informatics (NCBI) database website. 2020.
    1. Biasini M., Bienert S., Waterhouse A., Arnold K., Studer G., Schmidt T. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42
    1. Kirchdoerfer R.N., Ward A.B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 2019;10:2342.
    1. SAVES . 2020. Structural Analysis and Verification Server Website.
    1. Williams C.J., Headd J.J., Moriarty N.W., Prisant M.G., Videau L.L., Deis L.N. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293–315.
    1. Laskowski R.A., Rullmann J.A.C., MacArthur M.W., Kaptein R., Thornton J.M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR. 1996;8:477–486.
    1. Eisenberg D., Lüthy R., Bowie J.U. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods in Enzymology: Elsevier. 1997:396–404.
    1. Pontius J., JRaSJW Deviations from standard atomic volumes as a quality measure for protein crystal structures. Journal of Molecular Biology. 1996;264:121–136.
    1. Hooft R.W., Vriend G., Sander C., Abola E.E. Errors in protein structures. Nature. 1996;381:272.
    1. Elfiky A.A. The antiviral Sofosbuvir against mucormycosis: an in silico perspective. Future Virology. 2020;0 null.
    1. Summers K.L., Mahrok A.K., Dryden M.D., Stillman M.J. Structural properties of metal-free apometallothioneins. Biochem. Biophys. Res. Commun. 2012;425:485–492.
    1. Lii J.H., Allinger N.L. Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals’ potentials and crystal data for aliphatic and aromatic hydrocarbons. J. Am. Chem. Soc. 1989;111:8576–8582.
    1. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461.
    1. Angela M., Lam C.E., Bansal S., Micolochick Steuer H.M., Niu C., Zennou V., Keilman M., Zhu Y., Lan S., Otto M.J., Furman P.A. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 2012;56:3359–3368.
    1. Elfiky A.A., GW A., EW M., M A. Software and Techniques for Bio-Molecular Modeling. Austin Publishing Group; USA: 2016. Hepatitis C viral polymerase inhibition using directly acting antivirals, a computational approach; p. 197.
    1. Lam M.J.O., Sofia M.J., Espiritu C., Bansal S., Steuer A.M., Bao D., Chang W., Bao C.N., Micolochick Eisuke Murakami H.M., Tolstykh T., Furman H.P.A. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 2010;285:34337–34347.
    1. Bullard-Feibelman K.M., Govero J., Zhu Z., Salazar V., Veselinovic M., Diamond M.S. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antivir. Res. 2017;137:134–140.
    1. Sacramento C.Q., de Melo G.R., Rocha N., LVB H., Mesquita M., de Freitas C.S. The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication. Sci Rep. 2017;7:40920. doi: 10.1038/srep40920.
    1. Cretton-Scott E., Perigaud C., Peyrottes S., Licklider L., Camire M., Larsson M. 588 in vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol. 2008;48:S220.
    1. Elfiky A.A., Elshemey W.M., Gawad W.A. 2′-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study. J. Comput. Theor. Nanosci. 2015;12:376–386.
    1. Zhou X.J., Pietropaolo K., Chen J., Khan S., Sullivan-Bolyai J., Mayers D. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob. Agents Chemother. 2011;55:76–81.
    1. Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svarovskaia E., Symonds W.T. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013;368:34–44.
    1. Glue P. 1999. The Clinical Pharmacology of Ribavirin. Seminars in Liver Disease; pp. 17–24.
    1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.
    1. Warren T.K., Jordan R., Lo M.K., Ray A.S., Mackman R.L., Soloveva V. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–385.
    1. Salentin S., Schreiber S., Haupt V.J., Adasme M.F., Schroeder M. PLIP: fully automated protein–ligand interaction profiler. Nucleic Acids Res. 2015;43
    1. Becke A.D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993;98:5648–5652.
    1. Leach A. 2nd edition. Prentice Hall; 2001. Molecular Modelling: Principles and Applications.
    1. Stewart J.J.P. Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. J. Mol. Model. 2007;13:1173–1213.
    1. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785–2791.
    1. Ibrahim I., Abdelmalek D., Elshahat M., Elfiky A. COVID-19 Spike-host cell receptor GRP78 binding site prediction. J. Infect. 2020 In press.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi